iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) • BTEK

BTEK current price
£5.01+4.81%

Capital at risk.

1W
-1.76%
1M
-1.57%
3M
-4.39%
6M
-5.47%
1Y
+4.81%
MAX
+35.41%
About iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Base currency
info
$ USD
Trading Cyrrency
info
GBP
ISIN
info
IE00BYXG2H39
Trading on
info
LSE
Ticker
info
BTEK
Fund manager
info
iShares
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.
Key facts & metrics
BasicAdvanced
Fund size
info
£457M
income
info
Distributing
Expense Ratio
info
35.00%
Dividend Yield
info
0.88527
Valuation
Price to prospective earnings
info
14.5
Price to book
info
4.15
Price to sales
info
3.4
Price to cashflow
info
11.29
Price
52-week High
info
£5.57
52-week Low
info
£4.68
50-day moving average
info
£5.27
200-day moving average
info
£5.18
Technicals
YTD
info
0.15%
Year 1
info
3.00%
Year 3
info
1.57%
Year 5
info
3.57%
Year 10
info
0.00%
Volatility Year 1
info
17.15%
Volatility Year 3
info
0.00%
Expected Return Year 3
info
0.00%
Sharpe Ratio
info
0.00%
Growth
Long term projected earnings
info
17.04%
Historical earnings
info
3.09%
Sales
info
1.76%
Cash flow
info
1.37%
Book value
info
5.49%
Sector breakdown
sector logo

Healthcare

% 100,00

Regional breakdown

North America

% 88,15

UK

% 5,80

Europe

% 4,84

Asia

% 1,21

Top 10 Holdings
provider logo
Gilead Sciences

10.5%

provider logo
Vertex

7.28%

provider logo
Amgen

7.13%

provider logo
Regeneron

5.44%

provider logo
AstraZeneca

4.14%

provider logo
Alnylam Pharmaceuticals

3.39%

provider logo
Biogen

2.37%

provider logo
Illumina

2.36%

provider logo
Argen-X

2.22%

provider logo
United Therapeutics

1.77%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

What is the name of BTEK?
Collapse

The name of BTEK is iShares Nasdaq US Biotechnology UCITS ETF USD (Acc).

What is the ticker of iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)?
Collapse

The primary ticker of iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) is BTEK.

What is the ISIN of iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)?
Collapse

The ISIN of iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) is IE00BYXG2H39.

What are the costs of iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Collapse

The total expense ratio (TER) of iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) amounts to 35.00% p.a. These costs are withdrawn continuously from the fund assets and already included in the performance of the ETF. You don't have to pay them separately.

Does iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) pay dividends?
Collapse

Yes, iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) does pay dividends.

What currency is iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) traded in?
Collapse

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) is traded in GBP.

Is iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) an accumulating or distributing ETF?
Collapse

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) is distributing.

Who is the fund manager of “iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)?
Collapse

The fund manager of iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) is iShares.

What is the fund size of iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)?
Collapse

The fund size of iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) is £457M.

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) news
thumb_up_alt
•Positive
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research•12h ago
thumbs_up_down
•Neutral
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA

NEW YORK, NY / ACCESSWIRE / December 20, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117787&wire=1 or contact Joseph E. Levi, Esq.

Accesswire•13h ago
thumbs_up_down
•Neutral
PCE Data Lower Than Expected, NVO Falls on New Obesity Drug, AFRM Upgraded

Jenny Horne joins the Futures show with live reaction to the latest PCE inflation data. November rate rose just 0.1% from October, but on an annual basis checked in at 2.4% On the stock front, Novo Nordisk (NVO) slid sharply after disappointing clinical data for its new obesity drug CagriSema.

Schwab Network•13h ago